Generic Name: elafibranor
Drug Class: NAFLD/NASH Medications
Approval Status: Experimental
Generic Version Available: No
Experimental Code: GFT505
Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. It is currently in Phase 3 clinical trials for treatment of non-alcoholic steatohepatitis (NASH).
Dosing Info: N/A
Last Reviewed: February 4, 2019